Despite multiple warnings from the Food and Drug Administration about its manufacturing processes, Nephron Pharmaceuticals, one of the largest employers in Lexington, has continued to face federal ...
After nephron-sparing treatment for RCC, patients with local recurrence had a higher mortality risk than patients without recurrence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback